Drugmakers raise 2018 U.S. prices, stick to self-imposed limits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- S&P 500, Dow at record highs on Mideast deal hopes; SpaceX, AMD drag
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Allergen (AGN) PT Lowered to $203 at BofA/Merrill Lynch; 'Cost Restructuring Mitigates Near-Term Headwinds... $300M-400M in Net Savings for 2018E'
January 4, 2018 6:20 AM ESTBofA/Merrill Lynch lowered its price target on Allergen (NYSE: AGN) to $203.00 (from $204.00) while maintaining a Buy rating, following the company's announced cost-cutting measures for 2018.
Analyst Jason Gerberry notes a reduced price target on the shares, as the company announced cost-cutting measures for 2018,... More
Horizon Pharma (HZNP) PT Raised to $18 at Citi on 2018 Outlook; 'Remain Constructive... Stability in Primary Care Franchise'
January 4, 2018 6:12 AM ESTCiti raised its price target on Horizon Pharma (NASDAQ: HZNP) to $18.00 (from $16.00) while maintaining a Buy rating, following a review of the company's outlook into 2018.
Analyst Liav Abraham notes an increased price target on the shares following an updated outlook for 2018 remains constructive... More
